About Numerate
Numerate is a Healthcare company based in San Bruno (United States) founded in 2007, and was acquired by ValoHealth in June 2019. Machine-learning algorithms are utilized for small-molecule drug design. Numerate has raised $16.3 million across 7 funding rounds from investors including HHS, Valo Health and Atlas Venture. The company has 11 employees. Numerate has completed 2 acquisitions, including DeepCrystal and Pharmix. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Services and Diversified. Its legal entity is NUMERAI LLC. Its competitors include Avidity Biosciences, Sutro Biopharma and Antheia; 3 of its 3 listed competitors have raised funding.
Company details
Numerate is applying novel machine-learning algorithms, at cloud scale, to solve the problems of small-molecule drug design. Its goal is to create a powerful new drug design platform that could rapidly deliver novel leads on targets with no need for a crystal structure and with very limited SAR data. It is leveraging their proprietary platform to build a broad pipeline of proprietary programs in a range of therapeutic areas, including cardiovascular, metabolic, and neurodegenerative diseases, focused on targets not typically addressed by computer-aided drug discovery.
- Headquarters San Bruno, United States
- Employees 11
- Stage Acquired
- SectorsHealthcare
- Website numerate.com
- Social LinkedIn X
- Acquired by ValoHealth (Jun 2019)
- Legal Name Numerai Llc
- Total Equity Funding$16.3M (USD)
in 7 rounds
- Latest Funding Round$2M (USD), Grant
Aug 2019
- InvestorsHHS
& 6 more
- Employee Count11
- Investments & AcquisitionsDeepCrystal
& 1 more
- Acquired byValoHealth
(Jun 2019)
Funding Insights of Numerate
Numerate has successfully raised a total of $16.3M across 7 strategic funding rounds. The most recent funding activity was a Grant round of $2 million completed in August 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $16.3M
- Total Rounds 7
- Last Round Grant — $2M
- First Round $2.56M
(Jun 2008)
- Investors Count 6
All 7 funding rounds of Numerate with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2019 | $2M | Grant | – | – | |
| Sep 2017 | $224,878 | Grant | – | – | |
| Aug 2017 | $224,927 | Grant | – | – | |
| Jun 2014 | $8.24M | Series C | – | Atlas Venture, Lilly Ventures | – |
| Mar 2009 | $5.5M | Series B | – | – | |
| Feb 2009 | $252,139 | Grant | – | – | |
| Jun 2008 | $2.56M | Series A | – | – |
7 investors in total: 7 institutional.
Investors in Numerate
Numerate has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include HHS, Valo Health and Atlas Venture.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| sbir.nih.gov | ||||
Venture capital firm investing in life science and biotechnology sectors | 1980 | atlasventure.com | Cambridge, United States | |
Early-stage life sciences investments are targeted in the healthcare sector. | lillyventures.com | Indianapolis, United States | ||
Venture capital firm focused on early-stage fintech, enterprise, web 3, consumer, and multiple sectors | 1995 | foundationcapital.com | Palo Alto, United States | |
Early-stage venture capital investments are made by Lanza techVentures. | lanzatechventures.com | Palo Alto, United States | ||
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
An AI-powered platform is utilized for drug discovery and development. | 2019 | valohealth.com | Boston, United States |
Investor details for Numerate
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Numerate
Numerate has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include DeepCrystal and Pharmix.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
AI-based geometric learning tools are provided for pharmaceutical applications. | deepcrystal.com | San Francisco, United States | 2014 | Oct 2017 | •••• | |
AI-based computational drug design solutions are provided for drug discovery. | pharmix.com | San Francisco, United States | 1999 | Feb 2008 | •••• |
Complete acquisition details for Numerate
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Numerate
6 dated milestones of Numerate across 12 years, from founding to its latest funding, stage changes and deals.
- Founded Numerate is founded.
- Acquisition Acquires Pharmix.
- Funding First funding round of $2.6M.
- Acquisition Acquires DeepCrystal.
- Exit Acquired by ValoHealth.
- Funding Latest funding round, Grant, of $2.0M.
Competitors of Numerate
Numerate has 3 listed competitors in our database, 3 of them funded. They include Avidity Biosciences, Sutro Biopharma and Antheia.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| aviditybiosciences.com | 2012 | San Diego, United States | $142.54M | 253 | Antibody-siRNA complexes are developed for cancer treatment. | |
| sutrobio.com | 2003 | United States | $171.85M | 235 | Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | |
| antheia.bio | 2013 | Palo Alto, United States | $152.37M | 50 | Yeast cells are genetically engineered to produce medicinal products. |
Detailed competitors of Numerate
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Numerate
Websites that share an audience with Numerate (numerate.com).
Websites whose visitors overlap most with Numerate. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| ngmbio.com | 100% | 3.3K | #4,587,249 | View details | |
| polyphor.com | 99% | View details | |||
| argentadiscovery.com | 99% | View details | |||
| alkermes.com | 99% | 22.7K | #1,117,011 | View details |
Top companies in Life Sciences Platforms & Tools
3 companies that operate in the same segment as Numerate (Life Sciences Platforms & Tools) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | |||
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | 1,111 | ||
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Numerate
Complete news archive for Numerate
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Numerate
Numerate was founded in 2007 and raised its 1st funding round 1 year after it was founded.
Numerate is headquartered in San Bruno, United States. It is registered at San Bruno, California, United States.
Numerate is a funded company, having raised a total of $16.3M across 7 funding rounds to date. The company's 1st funding round was a Series A of $2.56M, raised on Jun 2008.
Numerate has 11 employees.
Numerate is applying novel machine-learning algorithms, at cloud scale, to solve the problems of small-molecule drug design. Its goal is to create a powerful new drug design platform that could rapidly deliver novel leads on targets with no need for a crystal structure and with very limited SAR data. It is leveraging their proprietary platform to build a broad pipeline of proprietary programs in a range of therapeutic areas, including cardiovascular, metabolic, and neurodegenerative diseases, focused on targets not typically addressed by computer-aided drug discovery.
Numerate's top competitors include Sutro Biopharma, Avidity Biosciences and Antheia.
Numerate has made 2 acquisitions, including DeepCrystal, and Pharmix.
Numerate has 7 investors. Key investors include HHS, Valo Health, Atlas Venture, Foundation Capital, and NIH SBIR/STTR.
Numerate operates through Numerai Llc.
Yes. Numerate was acquired by ValoHealth in June 2019.